BIOCYTOGEN plans to issue A-shares for listing on the Sci-Tech Innovation Board, raising RMB 1.185 billion

AASTOCKS
2025.11.03 14:53

BIOCYTOGEN-B (02315.HK) announced that it plans to apply for the issuance of up to 99.8496 million A shares and to apply for listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The A share issuance application has been reviewed and approved by the Listing Review Committee of the Shanghai Stock Exchange and has received registration approval from the China Securities Regulatory Commission.

The proceeds of approximately RMB 1.185 billion are intended to be used for the construction of a drug early-stage research and development service platform, antibody drug research and evaluation projects, preclinical research and development projects, and to supplement working capital. Currently, the A share issuance price has not yet been determined

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.